Literature DB >> 18818107

"Cancer stem cells"-lessons from Hercules to fight the Hydra.

Felix Roman Moltzahn1, Jens-Peter Volkmer, Daniel Rottke, Rolf Ackermann.   

Abstract

Following the initial identification of hematopoietic tumor stem cells, such cells were also found in several solid tumor types. In urology, cancer stem cells have only been found in prostate tumors so far. The concept and detection of tumor stem cells rely heavily on findings derived from stem cell research. Therefore, in addition to identifying and characterizing urologic tumor stem cells, research in uro-oncology should also aim at better understanding the stem-cell biology of urologic organs. Insights in similarities and differences gleaned from these studies could be used to develop strategies for targeted destruction of tumor stem cells while sparing the physiological stem cells. The main target of future curative therapies in uro-oncology must therefore be the central, immortal head of the Hydra, the tumor stem cell.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18818107     DOI: 10.1016/j.urolonc.2008.07.009

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  7 in total

1.  Targeting cancer stem cells: a new therapy to cure cancer patients.

Authors:  Yapeng Hu; Liwu Fu
Journal:  Am J Cancer Res       Date:  2012-04-28       Impact factor: 6.166

Review 2.  Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.

Authors:  Richard T Bryan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-02-05       Impact factor: 6.237

3.  CD117⁺ cells in the circulation are predictive of advanced prostate cancer.

Authors:  Bethany A Kerr; Ranko Miocinovic; Armine K Smith; Xiaoxia Z West; Katherine E Watts; Amanda W Alzayed; Joseph C Klink; Maria C Mir; Tiffany Sturey; Donna E Hansel; Warren D Heston; Andrew J Stephenson; Eric A Klein; Tatiana V Byzova
Journal:  Oncotarget       Date:  2015-01-30

4.  A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics.

Authors:  Naomi Harner-Foreman; Jayakumar Vadakekolathu; Stéphanie A Laversin; Morgan G Mathieu; Stephen Reeder; A Graham Pockley; Robert C Rees; David J Boocock
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

Review 5.  Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis.

Authors:  Koran S Harris; Bethany A Kerr
Journal:  Stem Cells Int       Date:  2017-06-11       Impact factor: 5.443

Review 6.  CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.

Authors:  Brittni M Foster; Danish Zaidi; Tyler R Young; Mary E Mobley; Bethany A Kerr
Journal:  Biomedicines       Date:  2018-03-08

7.  CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance.

Authors:  Koran S Harris; Lihong Shi; Brittni M Foster; Mary E Mobley; Phyllis L Elliott; Conner J Song; Kounosuke Watabe; Carl D Langefeld; Bethany A Kerr
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.